The escalating U.S.-Iran conflict has sent shockwaves through the global pharmaceutical supply chain, with the prices of critical Active Pharmaceutical Ingredients (APIs) and key starting materials (KSMs) nearly doubling (2x) in the last three weeks.
As India imports nearly 70% of its bulk drugs (the raw chemicals used to make medicine), the disruption in the Persian Gulf has created an “input cost nightmare” for domestic manufacturers.
Why the “2x” Spike is Hitting Now
The pharmaceutical industry is heavily dependent on the petrochemical industry, making it hypersensitive to the Strait of Hormuz blockade.
1. The Solvents Crisis
Almost every medicine requires chemical solvents like Acetone, Methanol, and Phenol during the manufacturing process.
- The Link: These solvents are byproducts of petroleum and natural gas.
- The Price Jump: With Brent crude hovering at $110/barrel, the cost of these solvents has surged by 90–110% since late February.
- Supply Cut: Major Iranian chemical plants, which previously supplied “grey market” solvents to Asia, are currently offline or under “War-time conservation” mode.
2. The Logistics “War Premium”
India’s “Pharma Capital,” Hyderabad, and manufacturing hubs in Gujarat (Baddi/Ankleshwar) are facing a logistics bottleneck.
- Air Freight: With the Persian Gulf airspace restricted, cargo flights are taking longer, more expensive routes. Air freight rates for temperature-sensitive drugs have jumped 120%.
- Insurance: “War Risk Insurance” for sea-bound chemical containers has made even non-Iranian shipments significantly more expensive.
Impact on Essential Medicines
Industry experts at the Indian Drug Manufacturers’ Association (IDMA) warn that if these input costs remain at “2x levels” for another 30 days, the retail prices of common medicines could rise by 15–20%.
| Drug Category | Key Affected Raw Material | Estimated Cost Increase |
| Painkillers (Paracetamol) | PAP (Para-amino Phenol) | +85% |
| Antibiotics (Azithromycin) | Erythromycin Thiocyanate | +60% |
| Diabetes (Metformin) | DCDA (Dicyandiamide) | +75% |
| Vitamins (B1, B6, B12) | Various Petchem Intermediates | +110% |
The “PLI” Shield: India’s Strategy
To combat this, the Government of India is accelerating the Production Linked Incentive (PLI) Scheme 2.0 for the pharma sector:
- Domestic Substitution: The govt has identified 35 critical APIs that were previously 90% dependent on imports. Manufacturers who produce these locally are being offered an immediate 10% cash-back incentive on incremental sales.
- Strategic Buffer: The Department of Pharmaceuticals is reportedly considering a “National API Buffer” to stockpile 3-6 months of essential raw materials to prevent future geopolitical price shocks.
- Price Cap Waivers: There is growing pressure on the NPPA (National Pharmaceutical Pricing Authority) to allow a one-time “Emergency Price Hike” for essential medicines under the National List of Essential Medicines (NLEM) to prevent manufacturers from stopping production due to losses.
Industry Outlook
“We are seeing a perfect storm,” says a senior executive at Dr. Reddy’s. “First, the solvent prices doubled, then the logistics costs tripled, and now we are dealing with a 48-hour ultimatum that could shut down the region’s power grid. We are scrambling to find alternative suppliers in South Korea and Brazil, but their prices are also reacting to the global oil spike.”
